Announcement re: Full year results

RNS Number : 8016F
Venture Life Group PLC
23 March 2022
 

23rd March 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Announcement re: Full year results for the year ended 31st December 2021

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces that the Company's auditors have been unable to meet the pre-agreed timetable for the approval of the results on 24th March 2022, citing resource issues. As a result of this delay, the Company expects to announce its results for the year ended 31st December 2021 in early April.

The Company reiterates its guidance stated in its trading update on 31st January 2022:

· Revenue of £32.6 million for the FY21(2020: £30.1 million), up 8% on the prior year;

· Revenue in the second half of the year was £18.7 million, an increase of 35% over the revenues in the first half of the year (£13.9 million);

· Adjusted EBITDA in line with market expectations;

· Momentum building in the business post acquisitions demonstrated by Q4 revenue 59% above that in Q3; and

· Net debt of £3.2m pre-IFRS16 (£7.3m IFRS16) reflecting a phasing effect on working capital as a result of higher receivables following strong Q4 revenue.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

 

Cenkos Securities plc (Nomad and Joint Broker)

 

+44 (0) 20 7397 8900

Michael Johnson/Russell Kerr (Sales)

Stephen Keys/Camilla Hume (Corporate Finance)

 

 

Singer Capital markets (Joint Broker)

 

+44 (0) 20 7496 3000

Jonathan Dighe (Sales)

Shaun Dobson/Alaina Wong (Corporate Finance)

 

 

 

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSEWFLDEESEID
UK 100

Latest directors dealings